MetLife (MET) Stock Forecast & Price Target

$68.85 -7.06 (-9.31%)

As of 10:50 AM Eastern

MetLife - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
0

Hold
1

Buy
13

Based on 14 Wall Street analysts who have issued ratings for MetLife in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a hold rating, and 13 have given a buy rating for MET.

Consensus Price Target

$94.85
37.77% Upside

According to the 14 analysts' twelve-month price targets for MetLife, the average price target is $94.85. The highest price target for MET is $109.00, while the lowest price target for MET is $80.00. The average price target represents a forecasted upside of 37.77% from the current price of $68.85.

Get the Latest News and Ratings for MET and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for MetLife and its competitors.

MET Analyst Ratings Over Time

Type	Current Forecast 4/4/24 to 4/4/25	1 Month Ago 3/5/24 to 3/5/25	3 Months Ago 1/5/24 to 1/4/25	1 Year Ago 4/5/23 to 4/4/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	11 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$94.85	$94.58	$88.62	$77.23
Forecasted Upside	37.77% Upside	13.72% Upside	7.79% Upside	5.61% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy

Remove Ads

MET Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MET Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

MetLife Stock vs. The Competition

Type	MetLife	Finance Companies	S&P 500
Consensus Rating Score	2.93	2.53	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	34.94% Upside	62.09% Upside	29.65% Upside
News Sentiment Rating	Positive News See Recent MET News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
4/2/2025	UBS Group 4 of 5 stars	Brian Meredith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$94.00 ➝ $98.00	+19.58%
4/2/2025	Piper Sandler 2 of 5 stars	John Barnidge Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$92.00 ➝ $94.00	+14.87%
4/2/2025	JPMorgan Chase & Co. 2 of 5 stars	Jimmy Bhullar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$88.00 ➝ $86.00	+5.94%
3/7/2025	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy
2/28/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Nigel Dally Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$101.00 ➝ $109.00	+28.10%
2/19/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Elyse Greenspan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$92.00 ➝ $97.00	+17.84%
2/12/2025	Keefe, Bruyette & Woods Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ryan Krueger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Outperform ➝ Outperform	$100.00 ➝ $98.00	+17.73%
2/7/2025	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Scott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Overweight ➝ Overweight	$96.00 ➝ $95.00	+13.10%
1/23/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Jack Matten Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$97.00	+13.09%
11/27/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Kligerman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$97.00 ➝ $99.00	+11.50%
Get the Latest News and Ratings for MET and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for MetLife and its competitors with MarketBeat's FREE daily newsletter.
9/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$89.00 ➝ $95.00	+14.71%
8/1/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$99.00 ➝ $96.00	+24.92%
7/23/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$83.00 ➝ $89.00	+18.26%
5/22/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$77.00 ➝ $80.00	+9.50%
1/8/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$70.00 ➝ $80.00	+16.08%
10/4/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Hold	$71.00	+18.33%
8/4/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$70.00 ➝ $74.00	+14.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:50 AM ET.

Should I Buy MetLife Stock? MET Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, March 30, 2025. Please send any questions or comments about these MetLife pros and cons to contact@marketbeat.com.

MetLife
Bull Case

Here are some ways that investors could benefit from investing in MetLife, Inc.:

MetLife, Inc. has a strong return on equity of 20.42%, indicating effective management and profitability in generating returns for shareholders.
The company recently announced a quarterly dividend of $0.545 per share, translating to an annualized dividend of $2.18 and a yield of 2.75%, which can provide a steady income stream for investors.
With a current stock price around $83.29, it is trading near its 50-day simple moving average, suggesting stability and potential for growth as it approaches its 12-month high of $89.05.
Analysts have a consensus rating of "Moderate Buy" for MetLife, Inc., with a target price averaging $94.58, indicating potential upside for investors.
The company has a manageable debt-to-equity ratio of 0.54, suggesting that it is not overly reliant on debt to finance its operations, which can be a sign of financial health.

MetLife
Bear Case

Investors should be bearish about investing in MetLife, Inc. for these reasons:

MetLife, Inc. reported earnings per share (EPS) of $2.08 for the last quarter, which was below analysts' expectations of $2.13, indicating potential challenges in meeting growth targets.
The current ratio and quick ratio are both at 0.16, suggesting that the company may face liquidity issues in meeting short-term obligations, which could be a concern for investors.
Despite a generally positive outlook, some analysts have downgraded their ratings, with StockNews.com moving from a "buy" to a "hold" rating, indicating mixed sentiments in the market.
MetLife's net margin of 6.19% is relatively modest, which may limit the company's ability to reinvest in growth opportunities compared to competitors with higher margins.
Recent price target adjustments by analysts, including reductions from firms like Keefe, Bruyette & Woods, may signal caution regarding the stock's near-term performance.

MET Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for MetLife is $94.85, with a high forecast of $109.00 and a low forecast of $80.00.
: 14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MetLife in the last year. There is currently 1 hold rating and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MET shares.
: According to analysts, MetLife's stock has a predicted upside of 37.77% based on their 12-month stock forecasts.
: MetLife has been rated by research analysts at Barclays, BMO Capital Markets, Cowen, JPMorgan Chase & Co., Keefe, Bruyette & Woods, Morgan Stanley, Piper Sandler, UBS Group, and Wells Fargo & Company in the past 90 days.
: Analysts like MetLife more than other "finance" companies. The consensus rating score for MetLife is 2.93 while the average consensus rating score for "finance" companies is 2.53. Learn more on how MET compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:MET) was last updated on 4/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MetLife (MET) Stock Forecast & Price Target